The 13th MEDICA START-UP COMPETITION 2024 has kicked off
The 13th MEDICA START-UP COMPETITION features a range of categories such as “AI in medicine”, “robotics”, “health apps”, “lab diagnostics” and “other”. The top 12 medical start-ups of 2024 will present their solutions at the pitch final (on 12 November) at the MEDICA INNOVATION FORUM.
The first award for 2023 was awarded to “MeMed BV”, the first diagnostic test to be approved by the FDA and receive a CE label which can use serum or venous blood to differentiate between bacterial and viral infections in just 15 minutes. “Our product helps clinics all over the world to make better decisions about antibiotic treatments”, says Yossi Horesh, Director of the US-Israeli company. MeMed has already established a strong position in the USA, Israel and Italy. Now, the young company is also expanding to Asia, the Middle East and other parts of Europe. Looking back at their success during the start-up competition at MEDICA 2023, Horesh adds: “Our participation in the competition kicked off a lot of productive discussions. For instance, we analysed the economic advantages of our system, particularly its capacity for reducing the use of antibiotics. We also engaged with the critical issue of treating patients with sepsis and predicting possible deterioration in a patient’s condition. Our next product, MeMed Universal Severity, will address these issues. It is designed to help clinicians better assess the risk if an infection is suspected.”
“We were in very good company as one of the finalists”
With the first ultrasound robot to bear a CE label, the Danish company Ropca took third place at last year’s MEDICA START-UP COMPETITION. Ropca has automated the process of ultrasound imaging and image analysis: The “ARTHUR” platform, a robot arm, and the artificial intelligence product “DIANA” help to overcome the growing challenge posed by increasing numbers of patients afftected by rheumatoid arthritis, hospital treatment costs and the shortage of specialists.
Johannes Schäeferhoff, CEO of Ropca, reports that the company had good experiences with MEDICA even before applying to the competition. In 2022, the company (founded in 2019) won the KUKA award for medical innovation and attracted particular attention from the trade fair audience. After the big on-stage pitch final as part of MEDICA 2023, Schäeferhoff can now report a recent successful round of investor funding and its outcome: “We are all about internationalisation now.” The system is primarily intended for large medical centres such as university hospitals and has the potential to reduce waiting times for rheumatology appointments. In Germany, the company plans to test screening with Ropca in several cities, and the list of appropriate indications could also be expanded. “We will be approved for osteoarthritis in the near future”, Schäeferhoff is sure.
Solutions for the "Internet of Medical Things"
The HEALTHCARE INNOVATION WORLD CUP shines a spotlight on the next generation of smart health devices, medical wearables, digital biomarkers, electroceuticals, smart plasters and more. First place at the MEDICA pitch 2023 went to DiaMonTech with a blood glucose measurement system that does away with needles completely. “As of today, there is no other device that performs this measurement with an equal level of precision”, says Thorsten Lubinski, CEO of the Berlin start-up. Instead of a needle, a beam of light is directed onto the skin. This light heats the glucose molecules in the skin almost exclusively. The increase in heat is so minimal that it cannot be felt, but it is certainly measurable. Based on this heat development, the device calculates the blood glucose value.